Clinical Director, Allogeneic Hematopoietic Stem Cell Transplantation, Dana-Farber Cancer Institute. Associate Professor of Medicine, Harvard Medical School
Oncology
Dr. Vincent M. Ho, MD
|
|
Give Review
Vincent M. Ho, MD works in the field of Oncology. He went to Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Dr. Vincent M. Ho is also published. He has 87 publications published. The lastest publication: "Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease.'
Publications
- Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease.
- A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A P...
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
- A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality.
- Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions.
- Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
- Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation.
- Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
- A PROGNOSTIC SCORE FOR ACUTE GRAFT-VERSUS-HOST DISEASE BASED ON BIOMARKERS: A MULTICENTER STUDY.
- Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplan...
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Characterization of Oral Involvement in Acute Graft-versus-Host Disease.
- A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease.
- Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
- Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802.
- Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome af...
- Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival.
- Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
- Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.
- White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
- Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease.
- BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis.
- Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
- Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
- ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
- Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.
- Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
- Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
- Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD.
- Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302.
- A Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease.
- Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
- KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.
- Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.
- Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
- Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
- Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
- Does iron overload really matter in stem cell transplantation?
- Interleukin-2 and regulatory T cells in graft-versus-host disease.
- Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
- Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
- The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.
- Cord colitis syndrome in cord-blood stem-cell transplantation.
- Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
- Hyperlipidemia and Statin Use after Allogeneic Hematopoietic Stem Cell Transplantation.
- Peritoneal Relapse of Testicular Seminomatous Germ Cell Tumor Treated Successfully With Salvage Chemotherapy and Autologous Stem Cell Transplantation.
- Ex Vivo T Cell Depletion of Allogeneic PBSC as Acute and Chronic GVHD Prophylaxis after Myeloablative HCT: Time to Reconsider?
- Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
- Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
- Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
- Invasive fungal disease after remote inoculation in transplant recipients.
- Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Co...
- Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
- Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
- Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation.
- CNS relapse in acute promyeloctyic leukemia.
- Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
- Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
- Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HL...
- Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
- Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation.
- Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after...
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
- Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
- Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with redu...
- Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
- The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantat...
- Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
- Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
- A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
- Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort ...
- Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
- Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
- Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
- Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
- Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
- Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease.
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
- Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
- Donor lymphocyte infusions.
- Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
- Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.
Schools
Roy J Lucille a Carver College Of Medicine At University Of Iowa
Rhode Island Hospital Lifespan
Doctors Specialties
- Hospital Medicine
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Desiree S. Gleason, DO |
|
Dr. Scot M. Sedlacek, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy K. Haase, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott A. Kono, DO |
|
|
Dr. Alexander R. Menter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brenda C. Eiser, MD |
|
Dr. Robert M. Jotte, MD
This Doctor is OpenDoctor Recommended.
|